Business
Microbix Updates Investor Presentation on its Website
In Response to OSC Requirements to Explain EBITDA (a non-IFRS measure) MISSISSAUGA, ON / AC...
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"Microbix Updates Investor Presentation on its WebsiteIn Response to OSC Requirements to Explain EBITDA (a non-IFRS measure) MISSISSAUGA, ON / ACCESS Newswire / January 9, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it has updated the investor presentation on its corporate website in response to comments of staff of the Ontario Securities Commission (OSC & OSC Staff) in relation to its usage of earnings before interest, taxes, depreciation, and amortization (EBITDA), a measure of financial results not formally-defined by International Financial Reporting Standards (IFRS).Specifically, over the course of a much broader OSC review of company continuous disclosure materials, it was identified that Microbix referred to EBITDA on two slides within its investor-oriented PowerPoint presentation. For those references, OSC Staff noted that Microbix did not provide the associated disclosures required by subsection 6.1(e) of National Instrument 52-112 (Non-GAAP and Other Financial Measures Disclosure) to explain the meaning of EBITDA to current or prospective investors with respect to:An explanation of the composition of the non-GAAP financial measureAn explanation of how the measure provides useful information to an investorA quantitative reconciliation of the non-GAAP measure to the most directly comparable financial measureOSC Staff identified the foregoing issue in the first of several letters to Microbix containing comments with respect to improving company disclosures and ensuring full compliance with the Ontario Securities Act (\"Act\") and the many OSC Staff Notices that provide issuers prescriptive guidance with respect to maintaining compliance with all rules and interpretations associated with the Act. In the course of updating all its continuous disclosure documents to fully incorporate and respect staff comments and guidance, Microbix updated the cited investor presentation for its fiscal Q3 2025 results without required additional disclosures related to EBITDA. Microbix's not responding to this particular OSC Staff comment resulted in this news release disclosure.The revised investor presentation including additional non-GAAP financial measure disclosure can be viewed or downloaded from the investors section of the Microbix w...